Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial

Neil A Goldenberg, MD PhD, Thomas C. Abshire, MD, Jonathan L Halperin, MD, William R. Hiatt, Craig M. Kessler, MD, John M Kittelson, PhD, Marilyn J. Manco-Johnson, MD, Alex Spyropoulos, MD, Phillipe Gabriel Steg, MD, Alexander G.G. Turpie, MD, Sam Schulman, MD PhD

Blood (2014) 124 (21): 4271.

https://doi.org/10.1182/blood.V124.21.4271.4271

Published: 2014

Journal Articles

Rivaroxaban for Thromboprophylaxis After Total Hip or Knee Replacement Surgery: Comparison of Outcomes of the XAMOS and RECORD Studies

Alexander G.G. Turpie, André Schmidt, Michael Rud Lassen, MD, Lorenzo Mantovani, Reinhold Kreutz, Gerlind Holberg, Sylvia Haas, MD

Blood (2012) 120 (21): 500.

https://doi.org/10.1182/blood.V120.21.500.500

Published: 2012

Journal Articles

Venous Thromboembolism Validation Study of the IMPROVE Risk Assessment Models in the Medical Patient (VTE-VALOURR),

Charles Edward Mahan, III, PharmD, Yang Liu, M Math, James D. Douketis, MD, Alexander G.G. Turpie, Undaleeb Dairkee, MD, Alex C Spyropoulos, MD

Blood (2011) 118 (21): 4218.

https://doi.org/10.1182/blood.V118.21.4218.4218

Published: 2011

Journal Articles

Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO

Daniel George, Giancarlo Agnelli, William Fisher, Ajay Kakkar, Michael R Lassen, Patrick Mismetti, Patrick Mouret, Francesca Lawson, Alexander G.G. Turpie

Blood (2011) 118 (21): 206.

https://doi.org/10.1182/blood.V118.21.206.206

Published: 2011

Journal Articles

The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery

Ajay K. Kakkar, MBBS, PhD, Giancarlo Agnelli, William D. Fisher, MD, Daniel George, Patrick Mouret, Michael R. Lassen, MD, Patrick Mismetti, Judith Murphy, Alexander G.G. Turpie

Blood (2010) 116 (21): 188.

https://doi.org/10.1182/blood.V116.21.188.188

Published: 2010

Journal Articles

The Effects of the Degree of Mobility Reduction and Prespecified Risk Factors on Venous Thromboembolism Rates in Acutely Ill Medical Patients in the EXCLAIM Study.

Roger D. Yusen, Russell D. Hull, Sebastian M. Schellong, Victor F. Tapson, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie

Blood (2007) 110 (11): 1862.

https://doi.org/10.1182/blood.V110.11.1862.1862

Published: 2007

Journal Articles

Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients in the EXCLAIM Study.

Victor F. Tapson, Russell D. Hull, Sebastian M. Schellong, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie, Roger D. Yusen

Blood (2007) 110 (11): 1863.

https://doi.org/10.1182/blood.V110.11.1863.1863

Published: 2007

Journal Articles

Extended-Duration Enoxaparin for Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients: An Evaluation of the EXCLAIM Study Based on a Recently Recommended Composite Efficacy Endpoint.

Sebastian M. Schellong, Russell D. Hull, Victor F. Tapson, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie, Roger D. Yusen

Blood (2007) 110 (11): 1870.

https://doi.org/10.1182/blood.V110.11.1870.1870

Published: 2007

Journal Articles

Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.

Bengt I. Eriksson, MD, PhD, Alexander G.G. Turpie, MD, PhD, Michael R. Lassen, MD, PhD, Martin H. Prins, MD, PhD, Giancarlo Agnelli, MD, PhD, Peter Kälebo, MD, PhD, Graham Wetherill, MSc, Lambertus Meems, MSc.

Blood (2007) 110 (11): 309.

https://doi.org/10.1182/blood.V110.11.309.309

Published: 2007

Journal Articles

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.

Michael R. Lassen, MD, Alexander G.G. Turpie, MD, Nadia Rosencher, MD, Lars C. Borris, MD, Walter Ageno, MD, Jay R. Lieberman, MD, Tiemo J. Bandel, MD, Frank Misselwitz, MD, PhD

Blood (2007) 110 (11): 308.

https://doi.org/10.1182/blood.V110.11.308.308

Published: 2007

Journal Articles

YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study.

Bengt I. Eriksson, MD, Alexander G.G. Turpie, MD, Michael R. Lassen, MD, Martin H. Prins, MD, Giancarlo Agnelli, MD, Marleen L. Gaillard, PhD, Bert Meems, MSc

Blood (2005) 106 (11): 1865.

https://doi.org/10.1182/blood.V106.11.1865.1865

Published: 2005

Journal Articles

Fondaparinux Combined with Intermittent Pneumatic Compression (IPC) Versus IPC Alone in the Prevention of Venous Thromboembolism after Major Abdominal Surgery: The Randomized APOLLO Study.

Alexander G.G. Turpie, FRCP, Kenneth A. Bauer, MD, Joseph A. Caprini, MD, Philip P. Comp, MD, Michael Gent, DSc, James E. Muntz, MD

Blood (2005) 106 (11): 279.

https://doi.org/10.1182/blood.V106.11.279.279

Published: 2005

Journal Articles

VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.

Sebastian M. Schellong, MD, Jan Beyer, MD, Kai Halbritter, MD, Benjamin Schmidt, MD, Alexander G.G. Turpie, MD, Bengt I. Eriksson, MD, PhD, Frank Misselwitz, MD, PhD, Peter Kälebo, MD

Blood (2005) 106 (11): 281.

https://doi.org/10.1182/blood.V106.11.281.281

Published: 2005

Journal Articles

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Alexander G.G. Turpie, MD, Kenneth Alan Bauer, MD, Lars Borris, MD, Ola E. Dahl, MD, PhD, William D. Fisher, MD, Michael Gent, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Louis M. Kwong, MD, Martin Homering, PhD, Frank Misselwitz, MD, PhD, Bengt I. Eriksson, MD, PhD

Blood (2005) 106 (11): 277.

https://doi.org/10.1182/blood.V106.11.277.277

Published: 2005

Journal Articles

Influence of Perceived Risk Factors for Bleeding on Venous Thromboembolism Prophylaxis Practices in Acutely Ill Medical Patients: Findings from IMPROVE.

Manuel Monreal, MD, Rainer B. Zotz, MD, Hervé Decousus, MD, Beng H. Chong, MD, PhD, Geno Merli, MD, Ricardo Pavanello, MD, Mario Pini, MD, Alexander G.G. Turpie, MD, Wei Huang, Frederick A. Anderson, Jr., PhD, for the IMPROVE Investigators

Blood (2005) 106 (11): 917.

https://doi.org/10.1182/blood.V106.11.917.917

Published: 2005

Journal Articles

Rates of Clinically Apparent Venous Thromboembolism and Death Resulting from Pulmonary Embolism among Unselected Hospitalized Acutely Ill Medical Patients Versus Rates Predicted from Clinical Studies.

Franco Piovella, MD, Frederick A. Anderson, Jr., PhD, Hervé Decousus, MD, Gordon FitzGerald, Jean-François Bergmann, MD, Ajay K. Kakkar, MD, PhD, Alex C. Spyropoulos, MD, Rainer B. Zotz, MD, Frederick A. Spencer, MD, Alexander G.G. Turpie, MD, for the IMPROVE Investigators

Blood (2005) 106 (11): 1620.

https://doi.org/10.1182/blood.V106.11.1620.1620

Published: 2005

Journal Articles

Benefit of Fondaparinux in Medical Patients: A Subgroup Analysis.

Alexander T. Cohen, Alexander S. Gallus, Bruce L. Davidson, Michael R. Lassen, Martin H. Prins, Witold Tomkowski, Alexander G.G. Turpie, Jan F.M. Egberts, Anthonie W.A. Lensing

Blood (2004) 104 (11): 4079.

https://doi.org/10.1182/blood.V104.11.4079.4079

Published: 2004

Journal Articles

Identification of Medical Patients Who Should Receive Venous Thromboembolism Prophylaxis.

Alexander T. Cohen, Raza Alikhan, Juan I. Arcelus, Jean-François Bergmann, Sylvia Haas, Geno J. Merli, Alex C. Spyropoulos, Victor F. Tapson, Alexander G.G. Turpie

Blood (2004) 104 (11): 1786.

https://doi.org/10.1182/blood.V104.11.1786.1786

Published: 2004

Journal Articles

A Prospective Registry on Venous Thromboembolic Events: Findings from PROVE.

Alexander G.G. Turpie, for the PROVE Investigators

Blood (2004) 104 (11): 1769.

https://doi.org/10.1182/blood.V104.11.1769.1769

Published: 2004

Journal Articles

The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE): Venous Thromboembolism Prophylaxis Practices in Acutely Ill Medical Patients.

Victor F. Tapson, Herve Decousus, Jean-Fran[ccedi]ois Bergmann, Beng H. Chong, James B. Froehlich, Ajay K. Kakkar, Geno J. Merli, Manuel Monreal, Mashio Nakamura, Riccardo Pavanello, Mario Pini, Franco Piovella, Alex C. Spyropoulos, Alexander G.G. Turpie, Rainer B. Zotz, Gordon FitzGerald, Frederick A. Anderson, Jr, for the IMPROVE investigators

Blood (2004) 104 (11): 1762.

https://doi.org/10.1182/blood.V104.11.1762.1762

Published: 2004

NARROW

Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial

Rivaroxaban for Thromboprophylaxis After Total Hip or Knee Replacement Surgery: Comparison of Outcomes of the XAMOS and RECORD Studies

Venous Thromboembolism Validation Study of the IMPROVE Risk Assessment Models in the Medical Patient (VTE-VALOURR),

Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO

The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery

The Effects of the Degree of Mobility Reduction and Prespecified Risk Factors on Venous Thromboembolism Rates in Acutely Ill Medical Patients in the EXCLAIM Study.

Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients in the EXCLAIM Study.

Extended-Duration Enoxaparin for Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients: An Evaluation of the EXCLAIM Study Based on a Recently Recommended Composite Efficacy Endpoint.

Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.

YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study.

Fondaparinux Combined with Intermittent Pneumatic Compression (IPC) Versus IPC Alone in the Prevention of Venous Thromboembolism after Major Abdominal Surgery: The Randomized APOLLO Study.

VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Influence of Perceived Risk Factors for Bleeding on Venous Thromboembolism Prophylaxis Practices in Acutely Ill Medical Patients: Findings from IMPROVE.

Rates of Clinically Apparent Venous Thromboembolism and Death Resulting from Pulmonary Embolism among Unselected Hospitalized Acutely Ill Medical Patients Versus Rates Predicted from Clinical Studies.

Benefit of Fondaparinux in Medical Patients: A Subgroup Analysis.

Identification of Medical Patients Who Should Receive Venous Thromboembolism Prophylaxis.

A Prospective Registry on Venous Thromboembolic Events: Findings from PROVE.

The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE): Venous Thromboembolism Prophylaxis Practices in Acutely Ill Medical Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only